Skip to content

    Navin Fluo.Intl.

    NAVINFLUOR
    Chemicals·29 Apr 2026
    Management Summary

    Navin Fluorine International Limited reported strong Q4 and FY26 results, demonstrating resilient growth across all business verticals despite a challenging global environment. The company achieved significant revenue and EBITDA growth, improved operational efficiency, and maintained a healthy balance sheet. Strategic capex projects are on track, and management remains focused on disciplined growth and long-term value creation, supported by a robust order book and diversified product portfolio.

    Highlights

    5
    • Q4 FY26 Revenue of ₹938 crores, up 34% YoY, marking 6 consecutive quarters of growth.

    • Q4 FY26 Operating EBITDA of ₹321 crores, up 80% YoY, with margin expansion to 34.2%.

    • FY26 Net Operating Revenues of ₹3,314 crores, up 41%, driven by broad-based momentum across all segments.

    • Net working capital days improved to 74 days from 90 days, reflecting stronger operational efficiency.

    • Final dividend of ₹8.6 per equity share declared, representing 430% of face value.

    Concerns

    3
    • HPP segment saw a sequential revenue decline in Q4 FY26 due to planned shutdowns and opportunistic catalyst recharge, impacting ₹15-16 crores.

    • Agrochemical market is undergoing a slow reset, with volume recovery but pricing lagging.

    • Potential for increased competition in R32 capacity by 2027, though management emphasizes quota importance.

    Key financials

    Metrics

    7

    Periods

    2

    Q4 FY26

    3
    • Revenue
      ₹938 Cr
      YoY+34%
    • Operating EBITDA
      ₹321 Cr
      YoY+80%
    • Operating EBITDA Margin
      34.2%

    FY26

    4
    • Net Operating Revenues
      ₹3,314 Cr
      YoY+41%
    • Operating EBITDA
      ₹1,082 Cr
      YoY+100%
    • Operating EBITDA Margin
      32.6%
    • PAT
      ₹664 Cr
      YoY+129.7%

    Segment breakdown

    • HPP Business₹393 Cr41.9%
    • Specialty Chemicals₹360 Cr38.3%
    • CDMO Business₹186 Cr19.8%
    Donut· Share of Q4 FY26 Revenue

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    0.0x EBITDA

    Dividend

    ₹8.6/share (final)

    Liquidity

    Liquidity disclosed

    Company maintains a strong balance sheet with continued focus on capital allocation.

    Guidance & targets

    8
    CategoryTargetPriority
    Capacity
    Additional HFC capacity (R32)
    15,000 metric tons per annum
    High
    Capex
    Dahej MPP debottlenecking capex
    Commissioning
    High
    Project Completion
    Chemours project
    Completion
    High
    Working Capital
    Net working capital days
    75-80 days
    High
    CDMO
    CDMO revenue target
    $100 million
    High
    Capacity Utilization
    Overall capacity utilization
    70-75%
    Medium
    Profitability
    EBITDA margin
    30% plus/minus 1-2%
    High
    HPP Business
    R32 revenue potential
    INR 600-825 crores
    Medium

    HFC R32 capacity commissioning

    Q3 FY27
    CurrentOn track
    TargetCommissioning in Q3 FY27

    Why it matters

    This new capacity is a key driver for future revenue generation and growth in the HPP segment.

    Our additional HFC capacity expansion equivalent to 15,000 metric tons per annum of R32 remains on track for commissioning in quarter 3 FY27.

    How to verify

    guidance_and_targets[metric='Additional HFC capacity (R32)']

    Risks & concerns

    5
    RiskSeverity

    Geopolitical uncertainties and supply chain disruptions

    Challenging global environment and geopolitical uncertainties, with implications on energy prices, logistics, and supply chain disruptions.Management acknowledged

    medium

    Raw material price inflation

    Inflation has gone through, but the company has been able to pass on costs to customers, maintaining 45 days inventory.Management acknowledged

    medium

    Agrochemical market reset and pricing lag

    Slow reset happening in the agrochemical market, with volume recovery but pricing lagging.Management acknowledged

    medium

    Potential R32 overcapacity by 2027

    Competition might add capacity, but management emphasizes that quota availability under Kigali rules is the key factor, not just capacity.Analyst downplayed

    low

    Global demand slowdown due to high oil prices

    Concern that sustained $150 oil prices could lead to global demand slowdown, though not currently observed by management.Analyst not addressed

    low

    Q&A highlights

    8

    “So far, we have not seen any disruption. We have seen inflation go through. But fortunately, we've also been able to pass on a lot of these back to the customers.”

    Addressed concerns about supply chain disruptions and the company's ability to pass on raw material inflation to customers, indicating resilience.

    asked by Sanjesh Jain

    2 min read6 chapters

    Detailed Narrative

    01

    Q4 and FY26 Performance Overview

    Navin Fluorine International Limited delivered a strong performance in Q4 FY26 and for the full financial year. Q4 FY26 consolidated revenue stood at ₹938 crores, marking a 34% year-on-year growth. Operating EBITDA increased by 80% year-on-year to ₹321 crores, with margins expanding to 34.2%. For the full year FY26, net operating revenues grew by 41% to ₹3,314 crores, and Operating EBITDA more than doubled to ₹1,082 crores, with margins at 32.6%, an expansion of 992 basis points. Profit after tax for FY26 was ₹664 crores, up 129.7% from ₹289 crores in FY25.

    02

    Segmental Performance Highlights

    All three business verticals contributed to the growth. The HPP business saw a 20% year-on-year revenue growth in Q4 FY26, reaching ₹393 crores, driven by improved realization and volume. The Specialty Chemicals vertical grew by 39% year-on-year to ₹360 crores in Q4 FY26, reflecting strong execution in both existing and new molecules. The CDMO business demonstrated robust growth, with Q4 FY26 revenue increasing by 61% year-on-year to ₹186 crores, supported by a balanced mix of early, late-stage, and commercial molecules.

    03

    Strategic Growth Initiatives & Capex Execution

    The company is actively executing several strategic projects. The AHF plant was successfully commissioned and commercial supplies have commenced. Additional HFC capacity expansion (15,000 metric tons per annum of R32) is on track for commissioning in Q3 FY27. The Dahej MPP debottlenecking capex is also progressing well, targeting commissioning in Q3 FY27. The Chemours project is on track for completion by end June, early July, which is expected to accelerate market adoption.

    04

    Financial Health and Capital Allocation

    Navin Fluorine maintains a strong financial position, with net working capital days improving to 74 days from 90 days, and an expected range of 75-80 days going forward. The net debt to equity ratio stood at a negligible 0.01x as of March 31, 2026. Both Return on Equity (ROE) and Return on Capital Employed (ROCE) improved to 20% and 21% respectively. The Board declared a final dividend of ₹8.6 per equity share, representing 430% of the face value.

    05

    Raw Material and Geopolitical Environment Impact

    Management acknowledged the challenging global environment and geopolitical uncertainties, which have implications on energy prices, logistics, and supply chain disruptions. However, the company has not experienced any material disruptions and has been successful in passing on raw material inflation to customers. They maintain a 45-day inventory to mitigate risks and focus on agility in response to market changes.

    06

    Outlook and Future Growth Drivers

    The company expects continued growth, with a focus on niche chemistries and value creation. They anticipate 70-75% capacity utilization in the coming year, up from 50-60% this year. The CDMO business aims for a $100 million revenue target by FY27. The HPP business is expected to benefit from increasing adoption of low GWP refrigerants and export opportunities, with R32 revenue potential estimated between ₹600-825 crores.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.